Qdenga: Crunch Time For First Product In Parallel Review Route For EU And Non-EU Markets
Takeda could soon learn whether the European Medicines Agency will recommend in favor of approving its dengue vaccine, which was reviewed under a new evaluation route that simultaneously targets EU and non-EU countries.
You may also be interested in...
Dengue Vaccine Qdenga & Nine Drugs Win EMA Thumbs Up
The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.
EU Moment of Truth For Abaloparatide & Advanced Therapy Tab-Cel
Radius’s abaloparatide, which was previously rejected by the European Medicine Agency, is among the latest products that are this week being considered for EU-wide marketing approval by the agency.
Mirum Awaits EMA Verdict On ‘Reprioritized’ Livmarli Filing
Mirum could soon find out if its decision to reprioritize its EU filings for its rare liver disease drug has paid off.